BGT226 was the most potent PI3K inhibitor identified (83.6% cytotoxicity), but its effects on neuroblastoma remain under-studied, and development has been discontinued following phase I/II trials in advanced adult solid tumors for lack of efficacy, inconsistent target inhibition and dose-limiting toxicities (58, 59). Here, PIK3CA is linked to neuroblastoma.